Award

P01 CA81534

Funded outputs count: 113

Funder award ID: P01 CA81534

OpenAlex ID: G3007936770

The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

2021 · Rong Chen, Jennifer Tsai, et al. · Blood Cancer Journal · 19

PDF

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

2021 · Timothy L. Chen, Bonnie Harrington, et al. · Journal of Hematology & Oncology · 19

PDF

Études de l’impact des anomalies génétiques dans l’initiation, l’évolution et la résistance au traitement dans la leucémie lymphoïde chronique : exemple de la mutation d’IKZF3 p.L162R et des anomalies de TP53

2020 · Grégory Lazarian

PDF

Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia

2019 · Dario Veneziano, Luisa Tomasello, et al. · Proceedings of the National Academy of Sciences · 66

PDF

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion

2019 · Shanye Yin, Rutendo G. Gambe, et al. · Cancer Cell · 92

PDF

miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients

2018 · Veronica Balatti, Luisa Tomasello, et al. · Blood · 38

PDF

MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia

2017 · Laura Z. Rassenti, Veronica Balatti, et al. · Proceedings of the National Academy of Sciences · 66

PDF

NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

2017 · Timothy L. Chen, Minh Tran, et al. · Blood · 14

PDF

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells

2017 · Prexy Modi, Kumudha Balakrishnan, et al. · Oncotarget · 8

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

2016 · Christopher C Oakes, Marc Seifert, et al. · Nature Genetics · 307

miRNA clusters as therapeutic targets for hormone-resistant breast cancer

2015 · Gianpiero Di Leva, Douglas G Cheung, et al. · Expert Review of Endocrinology & Metabolism · 21

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

2015 · Viralkumar Patel, Michael J. Keating, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20

Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

2015 · Alessandra Ferrajoli, Cristina Ivan, et al. · EBioMedicine · 43

PDF

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

2015 · K Balakrishnan, M Peluso, et al. · Leukemia · 166

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

2015 · Yuh-Ying Yeh, Hatice Gulcin Ozer, et al. · Blood · 160

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

2015 · Fabiola Cervantes-Gomez, Betty Lamothe, et al. · Clinical Cancer Research · 222

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

2015 · James S. Blachly, Amy S. Ruppert, et al. · Proceedings of the National Academy of Sciences · 46

PDF

Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers

2015 · Christopher DeBoever, Emanuela M. Ghia, et al. · PLoS Computational Biology · 211

PDF

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

2015 · Qingshan Yang, Prexy Modi, et al. · Clinical Cancer Research · 222

Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells

2014 · Viralkumar Patel, Kumudha Balakrishnan, et al. · Blood · 38

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

2014 · Shuai Dong, Daphne Guinn, et al. · Blood · 98

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia

2014 · Yuh-Ying Yeh, Rong Chen, et al. · Oncotarget · 47

PDF

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia

2014 · Bing Cui, Liguang Chen, et al. · Blood · 208

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

2014 · Rainer Claus, David M. Lucas, et al. · Blood · 70

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells

2014 · Amal A. El-Mabhouh, Mary L. Ayres, et al. · Blood · 18